


Technological Platform / Bergonié Institute or CHU

Name	Molecular Pathology Unit	
Platform coordinator(s)	Dr. Isabelle SOUBEYRAN, MD, PhD Coordinator of the Molecular Pathology Unit Biopathology Department –Bergonié Institute – “PGMC d’Aquitaine” I.Soubeyran@bordeaux.unicancer.fr/ +33(0)5 56 33 04 36 website: https://www.bergonie.fr/diagnostic-et-traitements/laboratoire/	
Type of services	Routine diagnostics & Collaborative research projects	
Activities	<p>In partnership with the Anatomocytopathology Unit, the Molecular Pathology unit employs molecular screening technologies, allowing for the identification of specific genetic alterations contributing to the diagnosis, prognosis or the identification of therapeutic targets. Thanks to its expertise and access to innovative technologies, the unit also actively participates in clinical research activities. To date, we are participating in 15 national clinical studies at the institute initiative, in clinical studies with industrial promoters as well as multiple internal pilot research projects.</p> <p>► Molecular biology: 3411 + 736 analysis ► FISH: 1951 + 25 analysis ► CGH Arrays: 182 + 268 assays</p> <p>Collaborative research project examples</p> <p>CIRSARC: Phase III clinical trial evaluating the potential benefit of intensified neoadjuvant chemotherapy in patients with operable soft tissue sarcoma considered at high risk of relapse according to the CINSARC signature / 334 patients/ 10 centers/ 2 platforms</p> <p>MULTIPLI: Multicentric study based on patients with inoperable and/or metastatic locally advanced soft tissue sarcoma (MULTISARC) or metastatic colorectal cancer (ACOMPLI) / 2396 patients / Within Genomic Medicine France 2025/1 platform</p> <p>BIP-AIRIC : Immunotherapy study based on BIP project (Bergonié Institute Profiling) : Fighting cancer by targeting molecular alterations with specific drugs in early clinical trials / 200 patients/ 4 centers/ 1 platform</p> <p>GREAT: Genomic BRCA and Extensive ovArian cancer Testing: Etude de cohorte pour évaluer les caractéristiques cliniques des patientes atteintes d’un cancer épithélial de l’ovaire en fonction de la présence dans la tumeur d’une mutation BRCA ou d’anomalies génomiques et moléculaires au-delà de BRCA. 4500 patientes/250 centres / Funding Arcagy Gineco</p>	
Key technologies	<ul style="list-style-type: none"> Genomic material extraction from FFPE tissues as well as liquid biopsies SANGER/ NGS Sequencing technique QPCR/RT-PCR / Droplet Digital PCR Molecular signature; EndoPredict (Myriad); CINSARC signature (Affymetrix, Clariom chip) Idylla technology (Biocartis) CGH Array (Affymetrix Oncoscan and Cytoscan, Agilent CGH technology) NGS RNASeq ciblé ARCHERDX; RNAseq total Trusight Affymetrix FISH: Fluorescent <i>in situ</i> hybridization 	
Please state no more than 5 facts illustrating the appeal or reputation of the platform	<ul style="list-style-type: none"> Participation on national and international research projects in collaboration with academic structure and/or private companies Participation in multidisciplinary board and molecular tumor board sessions Active participation in University Teaching: Molecular pathology inter-university diploma, Molecular pathology EPU, International masters, University diplomas in oncology and cytogenetic Center of reference for Medical student, PhDs Student training in Biology, oncology or anatomocytopathology Participation and intervention at national and international meetings 	
Please state the platform's major publications	Leroy L, <i>et al.</i> . Thyroid. 2019 Dec 31. Croce S <i>et al.</i> Mod Pathol. 2019 Jul;32(7):1008-1022. Cousin S, <i>et al.</i> J Hematol Oncol. 2018 Jun 25;11(1):86. Bonhomme B, <i>et al.</i> Thyroid. 2017 May;27(5):682-692. Godbert Y, <i>et al.</i> J Clin Oncol. 2015 Jul 10;33(20):e84-7. <div style="text-align: right;">(within the last 5 years)</div>	
People in the platform with their degree	Houda BEN REJEB MD, Benjamin BONHOMME MD, Sabrina CROCE MD, Emmanuel KHALIFA MD, Gaëtan MACGROGAN MD, Isabelle SOUBEYRAN, MD, PhD / Isabelle HOSTEIN, PhD, Claire LARMONIER, PhD/Bioinformaticien: Mme Jennifer CHIRON / Technicians: Marine BAIRRAO, Larry BLANCHARD, Aymeric DELABARRE, Yannick LEGER, Estelle MARION, Laetitia NEGRE-MAYEUR, Flora REBIER, Charlotte PRIMOIS, Julie SENTIS, Ghislaine SIERANKOWSKI / Manager: Karine PEUTAT / Quality manager: Anulka KESTEMONT.	
Innovation technologic or research in the future 5 years	<ul style="list-style-type: none"> CIRCULAR: Assessment of the added value of liquid biopsy compared to FFPE samples for the treatment of advanced non-small cell lung cancer / 550 patients / 10 centers and platforms/ Funding Astra Zeneca. DEAR: DEtection of ALK rearrangements by RNA-seq Archer / Funding Takeda Impact of TCR structure analysis in the prediction of immunotherapy responses GIRONDE : Genomic index evaluation by Oncoscan CNV FFPE Assay (Affymetrix) versus SurePrint G3 (Agilent) / 65 samples / Funding ThermoFisher 	

